2024. Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s441. DOI:https://doi.org/10.25251/skin.8.supp.441.